Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging

Neoplasia (United States)

Volumn 14, Issue 10, 2012, Pages 964-973

  Jarzyna, Peter A ^a,b   Deddens, Lisette H ^c   Kann, Benjamin H ^a   Ramachandran, Sarayu ^a   Calcagno, Claudia ^a   Chen, Wei ^a   Gianella, Anita ^a   Dijkhuizen, Rick M ^c   Griffioen, Arjan W ^d   Fayad, Zahi A ^a   Mulder, Willem J M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CY 7; IRON OXIDE NANOPARTICLE; MAGNETITE; METAL NANOPARTICLE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RHODAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE IMAGING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFRARED RADIATION; LIGHT SCATTERING; MOUSE; NANOEMULSION; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TUMOR VASCULARIZATION;

EID: 84867797734     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121148     Document Type: Article

References (42)

1. Jain RK and Stylianopoulos T (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7, 653-664.
2. Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-286.
3. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, and Ferrara N (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57, 4593-4599.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
5. Chung AS, Lee J, and Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10, 505-514.
6. Shojaei F (2012). Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320, 130-137.
7. Ebos JM and Kerbel RS (2011). Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8, 210-221.
8. Moreno Garcia V, Basu B, Molife LR, and Kaye SB (2012). Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 18, 3750-3761.
9. Lederle W, Palmowski M, and Kiessling F (2012). Imaging in the age of molecular medicine: monitoring of anti-angiogenic treatments. Curr Pharm Biotechnol 13, 595-608.
10. Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A, and Ribatti D (2008). Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol 23, 601-607.
11. Calcagno C, Mani V, Ramachandran S, and Fayad ZA (2010). Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis 13, 87-99.
12. Cao Y (2011). The promise of dynamic contrast-enhanced imaging in radiation therapy. Semin Radiat Oncol 21, 147-156.
13. Deshpande N, Pysz MA, and Willmann JK (2010). Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis 13, 175-188.
14. Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, de Jong JR, Price PM, Hollema H, Hospers GA, et al. (2011). VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 71, 143-153.
15. Hak S, Reitan NK, Haraldseth O, and de Lange Davies C (2010). Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles. Angiogenesis 13, 113-130.
16. Snoeks TJ, Lowik CW, and Kaijzel EL (2010). 'In vivo' optical approaches to angiogenesis imaging. Angiogenesis 13, 135-147.
17. de Lussanet QG, Beets-Tan RG, Backes WH, van der Schaft DW, van Engelshoven JM, Mayo KH, and Griffioen AW (2004). Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. Eur J Cancer 40, 1262-1268.
18. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, Lambin P, Beets GL, van Engelshoven JM, and Beets-Tan RG (2005). Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63, 1309-1315.
19. Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, et al. (2012). Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 22, 1451-1464.
20. Barrett T, Brechbiel M, Bernardo M, and Choyke PL (2007). MRI of tumor angiogenesis. J Magn Reson Imaging 26, 235-249.
21. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, and Stadler WM (2008). Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26, 4572-4578.
22. Jarzyna PA, Gianella A, Skajaa T, Knudsen G, Deddens LH, Cormode DP, Fayad ZA, and Mulder WJ (2010). Multifunctional imaging nanoprobes. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2, 138-150.
23. Medarova Z, Rashkovetsky L, Pantazopoulos P, and Moore A (2009). Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 69, 1182-1189.
24. Mulder WJ and Griffioen AW (2010). Imaging of angiogenesis. Angiogenesis 13, 71-74.
25. Akers WJ, Zhang Z, Berezin M, Ye Y, Agee A, Guo K, Fuhrhop RW, Wickline SA, Lanza GM, and Achilefu S (2010). Targeting of ανβ3-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles. Nanomedicine (Lond) 5, 715-726.
26. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, et al. (2010). RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 24, 1689-1699.
27. van Tilborg GA, Mulder WJ, van der Schaft DW, Reutelingsperger CP, Griffioen AW, Strijkers GJ, and Nicolay K (2008). Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia 10, 1459-1469.
28. Lanza GM, Caruthers SD, Winter PM, Hughes MS, Schmieder AH, Hu G, and Wickline SA (2010). Angiogenesis imaging with vascular-constrained particles: the why and how. Eur J Nucl Med Mol Imaging 37(suppl 1), S114-S126.
29. Jarzyna PA, Skajaa T, Gianella A, Cormode DP, Samber DD, Dickson SD, Chen W, Griffioen AW, Fayad ZA, and Mulder WJ (2009). Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials 30, 6947-6954.
30. Fukumura D, Yuan F, Monsky WL, Chen Y, and Jain RK (1997). Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 151, 679-688.
31. van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MG, Tran MG, Sciot R, Hauben E, Hogendoorn PC, et al. (2005). Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65, 11520-11528.
32. Hillen F, Kaijzel EL, Castermans K, Oude Egbrink MG, Lowik CW, and Griffioen AW (2008). A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors. Biochem Biophys Res Commun 368, 364-367.
33. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, Parker JA, Mihaljevic T, Laurence RG, Dor DM, et al. (2004). Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22, 93-97.
34. Nakayama A, del Monte F, Hajjar RJ, and Frangioni JV (2002). Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging 1, 365-377.
35. De Grand AM and Frangioni JV (2003). An operational near-infrared fluorescence imaging system prototype for large animal surgery. Technol Cancer Res Treat 2, 553-562.
36. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, Koning GA, Griffioen AW, and Nicolay K (2005). MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 19, 2008-2010.
37. Hak S, Helgesen E, Hektoen HH, Huuse EM, Jarzyna PA, Mulder WJ, Haraldseth O, and Davies CD (2012). The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano 6, 5648-5658.
38. Kessinger CW, Togao O, Khemtong C, Huang G, Takahashi M, and Gao J (2011). Investigation of in vivo targeting kinetics of ανβ3-specific superparamagnetic nanoprobes by time-resolved MRI. Theranostics 1, 263-273.
39. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Belien JA, de Waal RM, Van Marck E, Magnani E, et al. (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38, 1564-1579.
40. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341, 1565-1571.
41. Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G, Mayo KH, Griffioen AW, and Nicolay K (2007). Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 21, 378-383.
42. Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Kann B, Dijk WJ, Thijssen VL, Griffioen AW, et al. (2011). Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano 5, 4422-4433.